Inhibrx Biosciences (INBX) Stock Soars 17% Following Impressive Phase 2 Cancer Data - Blockonomi

Shares of Inhibrx Biosciences climbed 17% Monday following encouraging Phase 2 clinical trial data for INBRX-106 in head-and-neck cancer treatment. • The experimental therapy paired with pembrolizumab... [3515 symbols]

Últimos artigos